Coty Inc (COTY): ~bought the oct 20th $4.50 calls today.....

~bought the oct 20th $4.50 calls today... COTY

Greedy G · 2020-11-10T16:12:15.1600000Z

~bought the oct 20th $4.50 calls today... COTY

Play Episode

7min

Proactive - Interviews for investors

Frontier IP Group CEO on H1 highlights, €25m 2D Photonics funding round

Frontier IP Group PLC (AIM:FIPP) CEO Neil Crabb talked with Proactive's Stephen Gunnion about the company’s half-year results and how its portfolio has continued to attract investment and commercial traction despite difficult market conditions. Crabb highlighted a €25 million funding round for 2D Photonics (formerly CamGraphIC), backed by major names including Sony, Bosch, NATO’s Innovation Fund, and Italy’s CDP. The company is developing graphene-based technology to enhance silicon performance in data centres and potentially defence applications. He noted broader progress across the portfolio, including funding raised by DeakinBio for its novel materials, and commercial wins for Alusid, such as new floor tile launches with Topps Tiles. GraphEnergyTech has partnered with institutions in Taiwan on graphene electrode technology, a move Crabb described as “a really broad spectrum of interest.” Crabb also emphasised the importance of cost-efficiency alongside innovation, noting, “It's a cost that's at the heart of this.” Frontier IP looks for technologies that can deliver real-world economic benefits, from solar panel efficiency to energy-saving USB-C power tech by Pulsiv. He also pointed to companies like Cambridge Raman Imaging and Nandi Proteins as part of a portfolio seeing strong investor interest, with corporate VCs, public sector groups and angel networks all engaging. For more updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future content. #FrontierIP #NeilCrabb #2DPhotonics #GrapheneTechnology #VentureCapital #DeepTech #CambridgeStartups #SustainableTech #GraphEnergyTech #AIMstocks #GreenInvesting #Semiconductors #InnovationFunding #TechInvestment #EnergyEfficiency

Proactive - Interviews for investors

ACG Metals CFO says hold hedge strategy is already paying off

ACG Metals Ltd chief financial officer Patrick Henze talked with Proactive's Stephen Gunnion about the company’s recently announced gold hedging strategy and its importance during ACG’s transition phase from precious to base metals. Henze explained that while ACG Metals is ultimately targeting copper production from its Gediktepe mine in Turkey by 2026, the mine currently generates strong cash flow from gold and silver. The company has moved to hedge 50% of its gold production at US$2,875 per ounce through January 2026, helping secure revenue in a volatile pricing environment. He noted: “We are currently producing gold and silver, which is a perfect transition for us to become a copper producer in ’26… we can benefit and protect a bit the cash flows by hedging the gold.” The hedge program, executed with Alpha, involves no cash outlay and allows ACG to retain upside exposure above US$3,065 per ounce on the hedged portion. Henze emphasised this strategy helps ACG provide more certainty to bondholders and equity investors by de-risking key financial metrics for 2025. The company remains unhedged on silver and copper, maintaining exposure for future upside. For more updates, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future content. #ACGMetals #GoldHedging #CopperTransition #GediktepeMine #MiningStrategy #GoldPrices #Commodities #CashFlowManagement #MiningInvestment #ProactiveInvestors

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Proactive - Interviews for investors

Titan Mining reports record 2024 production, expands resources

Titan Mining President Rita Adiani joined Steve Darling from Proactive to discuss the company’s year-end results, highlighting record production and strong financial performance in 2024. The company met the upper end of its production guidance, while costs were 10% lower than the low end of its all-in sustaining cost (AISC) guidance. In Q4 2024, Titan Mining produced 21.7 million pounds of payable zinc, marking a 56% increase compared to Q4 2023. Total full-year 2024 production reached 59.5 million pounds. The company also posted Q4 revenues of $26.3 million, representing a 318% increase from Q3 2024 and a 241% increase from Q4 2023. Adiani also shared updates on the company’s mineral resource expansion, noting that Titan completed an updated mineral resource estimate and extended the mine life for ESM’s zinc operations until 2033. The updated estimate reports a 22% increase in measured and indicated contained zinc pounds compared to the 2020 resource estimate. In addition to its zinc operations, Titan completed a maiden mineral resource estimate for the Kilbourne Graphite Project. The project now holds an open-pit constrained inferred mineral resource of 22 million U.S. short tons, with an average grade of 2.91% (Cg), containing 653,000 tons of graphite at a 1.50% cut-off grade. #proactiveinvestors #titanminingcorporation #tsx #ti #otcqb #timcf #TitanMining #ZincProduction #GraphiteMining #BatteryMetals #CriticalMinerals #MiningStocks #TSX #RitaAdiani #EVMaterials #GraphiteUSA #MiningExpansion #AgustaGroup #ProactiveInvestors

Followers	196
Posts	21186
Boards Moderated	0
Alias Born	01/04/2014

Volume:	9,176,185
Day Range:	4.765 - 5.12
Bid:
Ask:
Last Trade Time:	7:58:35 PM EDT
Total Trades:	36,226

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

COTY Detailed Quote

Recent COTY News

More COTY News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent COTY News

Go Ad-Free